As we return from an energizing week at SCOPE 2026 in Orlando, one thing is clear: the industry conversation has evolved. The focus has shifted from experimentation to execution — from “Should we modernize?” to “How…
Clinical trials are becoming increasingly global. Studies now run across countries, involve participants from different cultures, and collect data from multiple healthcare systems. In principle, this should support broader representation and stronger evidence. But in practice,…
Rare Disease Day is observed every year on the last day of February. In the United States, a disease is considered rare (or orphan) when it affects fewer than 200,000 people. While each condition may impact…
Team TrialX at SCOPE 2026: Sharib Khan (Co-founder & CEO), Wes Martz (Senior Director of Client Services), Beth Dickson (VP, Business Development), and Brandon Ramos (Sales Development Representative) SCOPE 2026 once again brought together leaders across…
“As we close 2025, I’m incredibly proud of what the TrialX team has built over more than 17 years of innovation and delivery. From launching our first app in 2008 with pioneers like Google Health and…
In 2022, OpenAI launched its first large-scale AI tool—an innovation that quickly reshaped how industries approached automation, creativity, and problem-solving. Since then, artificial intelligence has become part of everyday workflows, turning time-intensive tasks into faster, data-driven…
This Halloween, we made sure language barriers don’t haunt clinical research. 👻 We’re proud to facilitate more inclusive clinical trials by helping top sponsors and study teams communicate with participants in multiple languages—equipping them with the tools to reach the…
